However, in prostate cancer, SHMT2 displays a more complex expression pattern, being elevated in early-stage or low-grade tumors but reduced in more advanced cases, suggesting a stage-dependent role (Chen et al., 2022). This evidence concerns the gene SHMT2 and prostate carcinoma.